Literature DB >> 16642418

The impact of syringe deregulation on sources of syringes for injection drug users: preliminary findings.

Sherry Deren1, Charles M Cleland, Crystal Fuller, Sung-Yeon Kang, Don C Des Jarlais, David Vlahov.   

Abstract

In 2001, New York State enacted legislation to allow the provision of syringes by pharmacies and healthcare providers without prescription (ESAP, the Expanded Syringe Access Demonstration Program). A longitudinal study of IDUs (n=130) found that pre-ESAP, about half used only the safest source (needle exchange programs [NEPs]). Post-ESAP implementation, ESAP sources were initiated by 14%. Frequency of injection was related to ESAP use and those who used unsafe (or possibly unsafe) sources were as likely to use ESAP as those who had previously used only NEPs. The findings indicate that providing multiple sources of safe syringes for IDUs is necessary.

Mesh:

Year:  2006        PMID: 16642418     DOI: 10.1007/s10461-006-9096-4

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  10 in total

1.  Pharmacy syringe purchase test of nonprescription syringe sales in San Francisco and Los Angeles in 2010.

Authors:  Alexandra Lutnick; Erin Cooper; Chaka Dodson; Ricky Bluthenthal; Alex H Kral
Journal:  J Urban Health       Date:  2013-04       Impact factor: 3.671

2.  Evaluating a statewide pilot syringe access program for injection drug users through pharmacies in California.

Authors:  Alex H Kral; Richard S Garfein
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

3.  The law (and politics) of safe injection facilities in the United States.

Authors:  Leo Beletsky; Corey S Davis; Evan Anderson; Scott Burris
Journal:  Am J Public Health       Date:  2008-01-02       Impact factor: 9.308

4.  Randomized, community-based pharmacy intervention to expand services beyond sale of sterile syringes to injection drug users in pharmacies in New York City.

Authors:  Natalie D Crawford; Silvia Amesty; Alexis V Rivera; Katherine Harripersaud; Alezandria Turner; Crystal M Fuller
Journal:  Am J Public Health       Date:  2013-07-18       Impact factor: 9.308

5.  Temporal trends in spatial access to pharmacies that sell over-the-counter syringes in New York City health districts: relationship to local racial/ethnic composition and need.

Authors:  Hannah L F Cooper; Brian H Bossak; Barbara Tempalski; Samuel R Friedman; Don C Des Jarlais
Journal:  J Urban Health       Date:  2009-11       Impact factor: 3.671

6.  Comparison of injection drug users accessing syringes from pharmacies, syringe exchange programs, and other syringe sources to inform targeted HIV prevention and intervention strategies.

Authors:  Abby E Rudolph; Natalie D Crawford; Danielle C Ompad; Ebele O Benjamin; Rachel J Stern; Crystal M Fuller
Journal:  J Am Pharm Assoc (2003)       Date:  2010 Mar-Apr 1

7.  Continuing HIV risk in New York City injection drug users: the association of syringe source and syringe sharing.

Authors:  Samuel M Jenness; Holly Hagan; Kai-Lih Liu; Travis Wendel; Christopher S Murrill
Journal:  Subst Use Misuse       Date:  2011       Impact factor: 2.164

8.  Who purchases nonprescription syringes? Characterizing customers of the Expanded Syringe Access Program (ESAP).

Authors:  Haven B Battles; Kirsten A Rowe; Christina Ortega-Peluso; Susan J Klein; James M Tesoriero
Journal:  J Urban Health       Date:  2009-11       Impact factor: 3.671

9.  I could take the judgment if you could just provide the service: non-prescription syringe purchase experience at Arizona pharmacies, 2018.

Authors:  Beth E Meyerson; Carrie A Lawrence; Summer Dawn Cope; Steven Levin; Christopher Thomas; Lori Ann Eldridge; Haley B Coles; Nina Vadiei; Amy Kennedy
Journal:  Harm Reduct J       Date:  2019-09-18

10.  Access to syringes for HIV prevention for injection drug users in St. Petersburg, Russia: syringe purchase test study.

Authors:  Ekaterina V Fedorova; Roman V Skochilov; Robert Heimer; Patricia Case; Leo Beletsky; Lauretta E Grau; Andrey P Kozlov; Alla V Shaboltas
Journal:  BMC Public Health       Date:  2013-03-01       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.